Good news! We’ve made it easier for Texas Children’s Health Plan members to log in to the MyChart website. Now, you can access all your MyChart health care features anytime, anywhere using our new sign-in widget. Click the link to log in now
¡Buenas noticias! Hemos hecho más fácil el inicio de sesión en MyChart para nuestros miembros de Texas Children’s Health Plan. Ahora puedes acceder a todas las funciones de cuidado médico de MyChart en cualquier momento y desde cualquier lugar mediante nuestro nuevo widget de inicio de sesión. Haz clic en el enlace para iniciar sesión.
Important UpdateActualización importante:
Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!
¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!
Call to action: Texas Children's Health Plan (TCHP) would like to inform providers that Effective for dates of service on or after October 1, 2026, Texas Medicaid will update the prior authorization criteria for teplizumab-mzwv (Tzield).
The U.S. Food & Drug Administration (FDA) has approved teplizumab-mzwv (Tzield) as a treatment to delay the decline in endogenous insulin production in pediatric patients who are 8 to 17 years of age who have recently been diagnosed with stage 3 type 1 diabetes (T1D).
Updated Prior Authorization Requirements
Teplizumab-mzwv (Tzield) is a cluster of differentiation 3 (CD3)-directed antibody. Teplizumab-mzwv (Tzield) therapy may be approved for treatment duration of up to 14 days when the therapy meets the following criteria:
It is being used to delay the onset of stage 3 T1D in adult and pediatric patients who are 1 year of age or older with stage 2 T1D.
It is being used to delay the decline in endogenous insulin production in pediatric patients who are 8 years to 17 years of age and have recently been diagnosed with stage 3 type 1 diabetes (T1D). These patients must meet the following criteria:
The patient has a diagnosis of stage 3 T1D confirmed by the documentation of at least one positive pancreatic islet cell antibody:
The patient has residual beta cell function, as indicated by peak stimulated C-peptide > 0.2 pmol/mL on a mixed-meal tolerance test (MMTT) or by an alternative method if appropriate and MMTT is not available.
Next step for providers: Providers should share this information with their staff.
